YemenTuberculosis profile
Population  2015 27 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.6 (1.1–2.1) 5.9 (4–8)
Mortality (HIV+TB only) 0.05 (0.038–0.065) 0.19 (0.14–0.24)
Incidence  (includes HIV+TB) 13 (11–15) 48 (42–54)
Incidence (HIV+TB only) 0.15 (0.11–0.18) 0.55 (0.42–0.68)
Incidence (MDR/RR-TB)** 0.34 (0.16–0.52) 1.3 (0.6–1.9)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.75 (0.45–1.1) 5.8 (4.7–6.9) 6.5 (5.1–7.9)
Males 0.79 (0.55–1) 5.5 (4.3–6.7) 6.3 (4.9–7.8)
Total 1.5 (1.2–1.9) 11 (10–12) 13 (11–15)
TB case notifications, 2015  
Total cases notified 7 699
Total new and relapse 7 654
          - % tested with rapid diagnostics at time of diagnosis 9%
          - % with known HIV status 15%
          - % pulmonary 67%
          - % bacteriologically confirmed among pulmonary 55%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 60% (52–68)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.13 (0.09–0.18)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 26 2%
          - on antiretroviral therapy 26 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  150
(81–220)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.92–3.7) 18% (11–25)  
% notified tested for rifampicin resistance 0% 11% 23
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 23, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 23, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 86% 9 437
Previously treated cases, excluding relapse, registered in 2014 66% 65
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 67% 9
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data